Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting.

Int J Cardiol Heart Vasc · 2021 · PMC8256176 · PMID 34258380

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Yet, this latter trial showed a strong trend but failed to show a statistically significant reduction in bleeding events in the dual therapy arm compared to TAT. 3.5 Rationale for choice of antithrombotic treatment The PIONEER-AF-PCI [15] trial used a modified dosage of rivaroxaban [31] .

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.